EC accused of doing Big Pharma’s bidding

Published on 11 October 2010 at 10:09

MSF (Médecins sans Frontières) has accused the European Commission of blocking the production of cheap generic drugs in the developing world, reports the Guardian. After the 2010 Doha declaration, generics companies could theoretically make cheap copies of patented HIV and other drugs. But according to the French NGO, the EC has recently been pushing for tougher patent rules in free trade negociations with India. “The EC wants to introduce ‘data exclusivity’,” the London daily reports, “which would stop a generic company registering a copy of a drug that does NOT have a patent for a period of time - usually five to eight years - unless it runs its own expensive and lengthy clinical trials.” Launching its Europe! Hands off our Medicine campaign on 7 October, MSF accused the Commission of caving in to multinational drug companies seeking to protect their drug monopolies, claiming that “millions of people across the developing world could see their source of affordable medicines dry up”. A Commission statement on the issue said that, “Patents are important, they need to be protected."

Tags

Was this article useful? If so we are delighted!

It is freely available because we believe that the right to free and independent information is essential for democracy. But this right is not guaranteed forever, and independence comes at a cost. We need your support in order to continue publishing independent, multilingual news for all Europeans.

Discover our subscription offers and their exclusive benefits and become a member of our community now!

Are you a news organisation, a business, an association or a foundation? Check out our bespoke editorial and translation services.

Support independent European journalism

European democracy needs independent media. Join our community!

On the same topic